John A. Sedor

John is a 30-year veteran of the pharmaceutical industry with a track record of creating value for shareholders at public and private companies.

Previously, Mr. Sedor served as President and Chief Executive Officer at Centeon, LLC, a joint venture between two major multinational corporations, Rhône-Poulenc Rorer and Hoechst AG. Previously, Mr. Sedor served as Executive Vice President at Rhône-Poulenc Rorer, Revlon Health Care and Parke-Davis. Mr. Sedor holds a Bachelor of Science degree in Pharmacy/Chemistry from Duquesne University, and has studied strategic marketing at both Northwestern University’s Kellogg Graduate School of Management and Harvard Business School. He has also attended Harvard’s Executive Forum.

Currently, Mr. Sedor is a Board Member, Pernix Therapeutics (NASDAQ: PTX), a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. He also serves on the Board of Directors for Velico Medical Inc, a clinical-stage company developing product-candidates for blood transfusions safety.